142 related articles for article (PubMed ID: 37827257)
1. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Wang Y; Lu Z; Xun G
J Affect Disord; 2024 Jan; 344():159-168. PubMed ID: 37827257
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
4. A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine.
Li Z; Wu TT; Xiong YT; Zhang XY; Bao YP; Guo LB; Han BJ; Li SX; Wang YF; Lu L; Wang XQ
Front Psychiatry; 2023; 14():1188175. PubMed ID: 37426111
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial.
Yan N; Hu S
BMC Psychiatry; 2024 May; 24(1):365. PubMed ID: 38750479
[TBL] [Abstract][Full Text] [Related]
6. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Diep C; Rosenek N; Khoo Y; Gandhi W; van Reekum CM; Ravindran AV; Ladha KS; Frey BN; Milev RV; Rotzinger S; Lam RW; Kennedy SH; Lou W; Salomons T; Bhat V
Psychiatry Res; 2022 Jun; 312():114557. PubMed ID: 35461118
[TBL] [Abstract][Full Text] [Related]
7. A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China.
Chen H; Lin Q; Lin T; Lin Y; Lin X; Chen R; Luo L; Lin F; Xiao Y
J Psychiatr Res; 2019 Jul; 114():133-140. PubMed ID: 31075722
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study.
Kadam RL; Sontakke SD; Tiple P; Motghare VM; Bajait CS; Kalikar MV
Indian J Pharmacol; 2020; 52(2):79-85. PubMed ID: 32565594
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
13. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
[TBL] [Abstract][Full Text] [Related]
14. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
15. Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial.
Huang ML; Luo BY; Hu JB; Wang SS; Zhou WH; Wei N; Hu SH; Xu Y
Aust N Z J Psychiatry; 2012 Mar; 46(3):257-64. PubMed ID: 22391283
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Sheffrin M; Driscoll HC; Lenze EJ; Mulsant BH; Pollock BG; Miller MD; Butters MA; Dew MA; Reynolds CF
J Clin Psychiatry; 2009 Feb; 70(2):208-13. PubMed ID: 19210951
[TBL] [Abstract][Full Text] [Related]
17. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
